JLJennifer F. Lai

Jennifer F. Lai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer F. Lai has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diabetes Management Using a Patient Navigator in a Native Hawaiian Population: Experiences and Perceptions of the Kilolani Project

    by Nani L. Morgan, Nina A. Lopez, Amanda T. Campbell, Marguerite Cazin, Lauralee U. Ana, Jennifer F. Lai, May Vawer, James Yess

    Native Hawaiians (NHs) are a historically oppressed population disproportionately burdened by diabetes and related complications. The Kilolani Project, a patient navigator-centered, chronic disease management program, targets upstream drivers of health among vulnerable NH adult patients with diabetes within an urban academic safety-net clinic. To investigate the impact of the Kilolani Project, we performed a qualitative study to examine patient perspectives. Our goal is to ensure that their values, needs, and priorities drive future navigator-based strategies and healthcare delivery. Fifteen current Kilolani Project patients participated in one of three focus group sessions. Each session followed a semi-structured format with open-ended questions regarding their experiences with the Kilolani Project, patient navigators, and healthcare in general. Iterative transcript readings and coding revealed seven core themes: (1) Humanistic approach, (2) Trusting relationships, (3) Improved access, (4) Trauma-informed care, (5) Self-efficacy, (6) Resilience, and (7) Ethnic concordance. The Kilolani Project created a safe and culturally relevant experience for NH patients. They felt seen, heard, and valued, which resulted in an improved healthcare experience, engagement, and empowerment. Importantly, trust was the cornerstone to building a provider–patient relationship. Such culturally informed approaches are necessary to close the gap in health disparities faced by our NH communities.


  • Arecoline in buccal cells reflects Areca nut dose

    by Jennifer F. Lai, Ana Joy Mendez, Xingnan Li, Lynne R. Wilkens, Thaddeus Herzog, Adrian A. Franke

    Areca nut (AN) is a carcinogen; its chewing cessation is, therefore, of worldwide interest. However, cessation biomarkers are lacking. We sought to establish arecoline in chewers' buccal cells (BCs) as a biomarker for AN dose. Self‐reported AN doses, expressed as the average AN load (“AANL”), the product of AN amount, chewing time, and chewing frequency, were correlated by regression analysis with chewers' BC arecoline, measured by liquid chromatography mass spectrometry. We then determined whether associations differed between Class 1 chewers (who consume AN alone or with slaked lime, leaf, and/or spices) and Class 2 chewers (who consume any combination of the aforementioned ingredients plus tobacco). Among the 103 chewers, 28 Class 1 and 39 Class 2 chewers had detectable arecoline levels, which were used for analyses. A linear regression of cube‐root transformed AANL on equally transformed BC arecoline levels provided the best model fit; resulting slopes and corresponding correlation coefficients were 0.86 and 0.40 (p < 0.01) for all; 1.09 and 0.51 (p < 0.01) for Class 1 chewers; 0.35 and 0.17 (p = 0.29) for Class 2 chewers; and 0.94 and 0.45 (p < 0.01), and 0.79 and 0.37 (p = 0.08), respectively, for those who included or excluded lime. Relationships between AANL and BC arecoline levels were similar between chewers who included or excluded lime (p = 0.76), but less between chewing classes (p = 0.14). This provides confidence that BC arecoline can generally act as a reliable biomarker for AN dose, useful for estimating efficacy in AN cessation studies and population‐based chewing assessments.

  • Salivary Areca and tobacco alkaloids for bioverification in the Betel Nut Intervention Trial

    by Adrian A. Franke, Xingnan Li, Thaddeus A. Herzog, Yvette C. Paulino, Grazyna Badowski, Lynne R. Wilkens, Jennifer F. Lai

    Background: The Betel Nut Intervention Trial (BENIT) is the first known randomized controlled intervention trial designed to help minority Pacific Islanders in Guam and Saipan quit chewing the carcinogenic Areca catechu nut (AN). We report the BENIT's saliva bioverification results against the self‐reported chewing status (“quitter” or “chewer”) at day 22 follow‐up.Material and Methods: AN‐specific (arecoline, arecaidine, guvacoline, and guvacine) and tobacco‐specific (nicotine, cotinine, and hydroxycotinine) alkaloids were analyzed in saliva from 176 BENIT participants by an established and sensitive liquid chromatography mass spectrometry‐based assay.Results: The combined four AN alkaloid levels decreased from baseline in quitters (n = 50) and chewers (n = 108) by 32% and 9%, respectively. In quitters, decreases were significant for arecoline (p = 0.044)—the most prominent AN alkaloid, along with arecaidine (p = 0.042) and nicotine (p = 0.011). In chewers, decreases were significant only for hydroxycotinine (p = 0.004). Similar results were obtained when quitters and chewers were stratified by treatment arm.Discussion: Salivary AN alkaloid levels generally agreed with self‐reported chewing status, which suggests the former can be used to verify the latter.Conclusion: Our results can help to objectively evaluate compliance and program effectiveness in AN cessation programs.


  • Improved oxytocin analysis from human serum and urine by orbitrap ESI‐LC‐HRAM‐MS

    by Adrian A. Franke, Xingnan Li, Chester Dabalos, Jennifer F. Lai

    Native circulating oxytocin (OT) levels in non‐pregnant/non‐lactating/non‐medicated humans are very low (≤ 8 pg/mL). The lower limit of detection (LLOD) of our previous liquid chromatography mass spectrometry (LC–MS) method (10–25 pg/mL) precluded their quantification in serum and urine. Thus, we sought to improve the LC–MS sensitivity of OT measurements in these matrices by hydrophobic tagging and solid phase extraction (SPE). In the former approach, OT was reduced then alkylated with N‐alkyl acetamide (C12, C14, C16, and C18) tags or derivatized using sulfonyl chloride‐based reagents. In the latter approach, native OT in serum and urine was concentrated by offline SPE using gradient acetonitrile washings after first crashing with acetonitrile. Peak urinary eluate fractions were further concentrated online then analyzed by orbitrap‐based LC–MS with electrospray ionization. All hydrophobic OT derivatives had lower sensitivity than native OT. Washing with a water‐acetonitrile gradient during SPE improved the LLOD of OT in spiked serum to 2.5 pg/mL, while adding a subsequent online‐concentration step improved the LLOD in spiked urine to 1–5 pg/mL and allowed us to detect OT in urine from lactating women. We were unable to improve the sensitivity of OT measurements by hydrophobic tagging or by derivatization using sulfonyl chloride‐based reagents. However, we were successful in improving the sensitivity of native OT measurements in serum and urine 2‐ and 5‐fold, respectively, from our previous orbitrap‐based LC–MS method. Offline SPE was mandatory for both matrices and a subsequent online‐concentration step was required for urine.


  • Areca alkaloids measured from buccal cells using DART‐MS serve as accurate biomarkers for areca nut chewing

    by Adrian A. Franke, Laura Biggs, Joanne Y. Yew, Jennifer F. Lai

    Background: Areca nut (AN) chewing is carcinogenic and biomarkers reflecting it are urgently needed to determine the effectiveness of emergent cessation programs. Buccal cells (BCs) may serve as an ideal matrix to measure such biomarkers; however, their utility for this purpose is unknown. Direct analysis in real time−mass spectrometry (DART−MS) is a sensitive technique that analyzes materials in the open air and requires minimal/no sample preparation. We utilized DART−MS to analyze BCs to test the usefulness of this method in measuring areca alkaloids as biomarkers for AN chewing.Methods: We applied DART−MS in positive‐ion mode to quantitate over time human BCs: (a) exposed ex vivo to betel quid extracts (BQE) consisting of young AN, Piper betle L. leaf, slaked lime, and tobacco; and (b) obtained from seven chewers before and after BQ chewing. Quantification was performed by normalizing DART−MS alkaloid signal intensities to cholesterol intensities.Results: Signals for areca alkaloids arecoline and arecaidine‐guvacoline were detected in BCs exposed ex vivo to BQE up to 7 days (the last day tested) after exposure and in BCs from chewers up to 3 days (the last day tested) post chewing.Discussion: The presence of alkaloid signals in BQ‐exposed BCs verified BCs as a valid matrix and DART−MS as a suitable technique to measure biomarkers for AN chewing and provided reliable information on AN chewing timing.Conclusion: DART−MS analyses of BCs can be used to accurately determine areca alkaloids as AN chewing biomarkers up to 3 days post chewing and possibly longer.


  • Oxytocin analysis from human serum, urine, and saliva by orbitrap liquid chromatography–mass spectrometry

    by Adrian A. Franke, Xingnan Li, Ariane Menden, Mary R. Lee, Jennifer F. Lai

    Oxytocin (OT) is a neurohormone that has gained interest recently due to its emerging role in cognition and social/emotional behaviors, including possibly depression and autism. OT is commonly measured using enzyme‐ or radio‐based immunoassays (RIA, ELISA), which lack specificity or are complicated to perform and involve hazardous radioactive material. We have developed a high resolution accurate‐mass (HRAM) liquid chromatography–mass spectrometry (LC–MS) method that separates interferences and selectively and accurately quantitates native OT from human serum, urine, and saliva after solid phase extraction. The doubly protonated OT ion m/z 562.25503 was selected for quantitation due its high signal intensity. With our method lower limit of detection (LLOD) of 5–25 pg/mL, we measured native OT in serum from pregnant women (16–24 pg/mL) and rats (350 pg/mL), and in serum, urine, and saliva from a healthy male after intranasal (IN) OT application of 100 IU and 20 IU and from a healthy post‐menopausal female after IN OT application of 100 IU. Peak levels were detected in serum, urine, and saliva 15–30 minutes after each dose then decreased to below detection limits 1–2 hours thereafter. We were unable to detect native OT in serum from non‐pregnant/non‐lactating/non‐medicated women due to levels known to occur below 5 pg/mL. The fast elimination of OT we found is in excellent agreement with the pharmacokinetics of OT in other studies. The effects on the central nervous system occurring after IN OT administration remains to be determined.


  • Open Access

    Vitamin D Deficiency in Cord Plasma from Multiethnic Subjects Living in the Tropics

    by Brunhild M. Halm, Jennifer F. Lai, Ian Pagano, William Cooney, Reni A. Soon, Adrian A. Franke

    Background: Vitamin D deficiency is commonly reported in high-latitude areas and in dark-pigmented individuals. However, nothing is known about vitamin D in cord blood from multiethnic subjects living in the tropics. Objective: Our study objective was to determine the prevalence of vitamin D deficiency in summer and winter in cord blood from multiethnic individuals in Hawai’i where sufficient sun irradiance occurs year-round for cutaneous vitamin D production. Methods: 25-Hydroxyvitamin D (25(OH)D) levels were quantified by enzyme immunoassay in 100 cord plasma samples from apparently healthy full-term newborns and their mothers. Stratification was performed by birth season and ethnicity. Results: Mean 25(OH)D levels were 24.5 ng/mL (9.1–68.3 ng/mL). Overall, 28% of samples were vitamin D deficient (p = 0.008). Cord plasmas from summer versus winter were higher overall (p = 0.001) and among Asians (p = 0.0003). Seasonal changes were correlated with sun irradiance overall (r = 0.43, p = 0.0001), among Caucasians (r = 0.45, p = 0.05), and among Asians (r = 0.45, p = 0.0001). Conclusion: Our results suggest that prenatal supplement recommendations of 400 IU vitamin D/day do not protect against vitamin D deficiency, even in subjects living in the tropics where ample sun irradiance exists for cutaneous vitamin D synthesis. The high prevalence of vitamin D deficiency we observed emphasizes the necessity for regular 25(OH)D monitoring, particularly during pregnancy and lactation, in dark-pigmented individuals, and during winter months.